Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers - Additional Information (Detail)

v3.8.0.1
Revenues from Contracts and Significant Customers - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended
May 11, 2015
Sep. 30, 2015
Mar. 31, 2015
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Stock Issued During Period, Value, Issued for Services       $ 1,000 $ 1,000  
Revenue Recognition Milestone Method Payments Due       500,000    
Payments for Fees     $ 1,000,000      
License and Services Revenue       400,000    
Collaborative Arrangement, Fixed Fee       500,000    
Return Reserve       700,000 100,000  
Customer One [Member]            
Sales Revenue, Goods, Gross       4,400,000 800,000  
Accounts Receivable, Net       3,000,000 800,000  
Customer Two [Member]            
Sales Revenue, Goods, Gross       3,900,000 500,000  
Accounts Receivable, Net       2,100,000 $ 500,000  
Customer Three [Member]            
Sales Revenue, Goods, Gross       $ 2,000,000    
Checkpoint Therapeutics, Inc [Member]            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners [1]       67.40%   62.00%
First Commercial Sale Milestone [Member] | Checkpoint Therapeutics, Inc [Member]            
Revenue Recognition Milestone Method Payments Due       $ 21,500,000    
Additional Sales Milestone [Member] | Checkpoint Therapeutics, Inc [Member]            
Revenue Recognition Milestone Method Payments Due       60,000,000    
Clinical Development Milestone [Member] | Checkpoint Therapeutics, Inc [Member]            
Revenue Recognition Milestone Method Payments Due       7,000,000    
Commercial Sales In Specified Territories [Member] | Checkpoint Therapeutics, Inc [Member]            
Revenue Recognition Milestone Method Payments Due       $ 14,500,000    
Dana Farber Cancer Institute [Member]            
Proceeds from Issuance of Common Stock $ 10,000,000          
Stock Issued During Period, Shares, Issued for Services 500,000 136,830        
Stock Issued During Period, Value, Issued for Services $ 32,500 $ 600,000        
Shares Issued, Price Per Share $ 0.065          
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners     5.00%      
Dana Farber Cancer Institute [Member] | First Commercial Sale Milestone [Member]            
Revenue Recognition Milestone Method Payments Due   21,500,000        
Dana Farber Cancer Institute [Member] | Additional Sales Milestone [Member]            
Revenue Recognition Milestone Method Payments Due   $ 60,000,000        
[1] Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.